Search research articles
Contact Us
Filters
Showing results (11-20 of 52) with videos related to
Page
of 6
Sort By:
Future Oncology (London, England)
|
June 4, 2020
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
Robin Kate Kelley, Jennifer W Oliver, Saswati Hazra, et al.
BMC Cancer
|
April 10, 2022
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
Anthony B El-Khoueiry, Tim Meyer, Ann-Lii Cheng, et al.
Cell
|
April 17, 2026
Hallmarks of liver cancer: Therapeutic implications
Josep M Llovet, Roser Pinyol, Silvia Affo, et al.
Nature Reviews. Disease Primers
|
February 12, 2024
Author Correction: Hepatocellular carcinoma
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews. Disease Primers
|
January 22, 2021
Hepatocellular carcinoma
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
The Oncologist
|
August 16, 2022
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017
Milind Javle, Sunyoung Lee, Nilofer S Azad, et al.
Cancer Discovery
|
September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study
Funda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2022
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Andrew X Zhu, Farshid Dayyani, Chia-Jui Yen, et al.
Clinical Pharmacology and Therapeutics
|
July 8, 2023
Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Michelle Green, et al.
Cancer
|
December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
Fen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 52) with videos related to
Sort By:
Page
of 6
Future Oncology (London, England)
|
June 4, 2020
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
Robin Kate Kelley, Jennifer W Oliver, Saswati Hazra, et al.
BMC Cancer
|
April 10, 2022
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
Anthony B El-Khoueiry, Tim Meyer, Ann-Lii Cheng, et al.
Cell
|
April 17, 2026
Hallmarks of liver cancer: Therapeutic implications
Josep M Llovet, Roser Pinyol, Silvia Affo, et al.
Nature Reviews. Disease Primers
|
February 12, 2024
Author Correction: Hepatocellular carcinoma
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews. Disease Primers
|
January 22, 2021
Hepatocellular carcinoma
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
The Oncologist
|
August 16, 2022
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017
Milind Javle, Sunyoung Lee, Nilofer S Azad, et al.
Cancer Discovery
|
September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study
Funda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2022
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Andrew X Zhu, Farshid Dayyani, Chia-Jui Yen, et al.
Clinical Pharmacology and Therapeutics
|
July 8, 2023
Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Michelle Green, et al.
Cancer
|
December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
Fen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Page
of 6